Common stock of the merged company, Celularity, Inc., to commence trading on the Nasdaq Capital Market under the ticker symbol “CELU” on July 19, 2021 Clinical pipeline includes multiple clinical...
The Brain Mapping Foundation and the Society for Brain Mapping and Therapeutics to celebrate this trailblazing scientist, surgeon, visionary leader and serial entrepreneur at the 18th Annual Gathering for the...
Arthrex to receive exclusive rights to distribute and commercialize Celularity’s placental-derived biomaterial products for orthopedics and sport medicine in the United States FLORHAM PARK, NJ, and NAPLES, FL, July 01,...
No dose limiting toxicity to date with outpatient administration of three doses (Days 0, 7 and 14) at total dose levels of 1.8, 3.6, and 5.4 Billion CYNK-001 cells, respectively...
Pharmaceutical industry veteran brings more than 20 years of business and technical operations experience across various commercial and development products FLORHAM PARK, N.J., – May 20, 2021 — Celularity Inc. (“Celularity”),...
Celularity to leverage Palantir’s next generation software and computational capabilities with their deep cellular data set to accelerate research and development activities Partnership includes equity investment by Palantir in Celularity...
NEW YORK, April 16, 2021 /PRNewswire/ — On April 14, 2021, GX Acquisition Corp. (“GX”) (NASDAQ: “GXGX”), provided information regarding a proposal to amend GX’s amended and restated certificate of incorporation (the “Charter”) to...
FLORHAM PARK, N.J., April 13, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies...
Presentations to showcase updates related to multiple Celularity programs in immuno-oncology and infectious disease FLORHAM PARK, N.J., April 09, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company,...
FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies...
FLORHAM PARK, N.J., March 09, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company focused on the development of innovative allogeneic placenta-derived cellular therapies, announced that Robert J....
FLORHAM PARK, N.J., Jan. 20, 2021 /PRNewswire/ — Celularity Inc., a clinical stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular therapies, today announced that Robert J. Hariri, M.D., Ph.D.,...
FLORHAM PARK, N.J., Jan. 13, 2021 /PRNewswire/ — Celularity Inc., a clinical-stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular therapies, today announced that its Lifebank division has released...
Celularity has entered into a definitive merger agreement with GX Acquisition Corp. (Nasdaq: “GXGX”); upon closing, shares of the combined company will be listed on Nasdaq under the ticker symbol...
FLORHAM PARK, N.J., Dec. 1, 2020 /PRNewswire/ — Celularity announced today that the independent Data Monitoring Committee (DMC) completed the first assessment of the ongoing Phase I/II CYNK-001-COVID-19 (CYNKCOVID) study (https://clinicaltrials.gov/ct2/show/NCT04365101) with CYNK-001 off-the-shelf, allogeneic,...
Celularity announced today that the first patient was dosed in a Phase I/II study of human placental hematopoietic stem cell derived NK cells (CYNK-001) for the treatment of adults with COVID-19 as part of a national clinical trial. The patient was treated at UC Irvine in California, the first CA site to open for patient enrollment with support from a COVID-19 Project grant awarded to Celularity by the California Institute for Regenerative Medicine (CIRM). Participating trial sites include Hackensack University Medical Center and Atlantic Health in New Jersey, MultiCare Health System in Washington State, Banner University Medical Center Phoenix in Arizona, the University of Arkansas in Arkansas, and UC Davis in California. The Principal Investigator is Corey Casper, M.D., MPH, of the Infectious Disease Research Institute (IDRI) ClinicalTrials.gov Identifier: NCT04365101.
Celularity, Inc. (”Celularity” or “the Company”) today announced that it has sold its UltraMIST® Ultrasound Healing Therapy asset to Sanuwave Health, Inc. [OTC PNK: SNWV] (“Sanuwave”) in connection with which...
University of California Irvine is the first California site participating in Celularity’s CYNK-001-COVID-19 clinical trial NCT04365101 using Celularity’s investigational immunotherapy to treat adults who tested COVID-19 positive in underserved and...
The expanded strategic collaboration includes the use of Celularity's proprietary CYNK-001 for treatment of SARS-CoV-2 virus, which causes COVID-19 and Acute Respiratory Distress Syndrome
Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update
Celularity Founder, Chairman and Chief Executive Officer, Robert J. Hariri, M.D., Ph.D., Dually Awarded for Pioneering Contributions in Medicine and Leadership
Celularity and Arthrex Enter into Exclusive Supply and Distribution Agreement for Multiple Commercial Products
Celularity Announces Expansion of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) Phase 1 Trial in Patients with Acute Myeloid Leukemia
Celularity Appoints Bradley Glover, Ph.D. as Executive Vice President and Chief Technology Officer
Celularity Enters into Multi-Year Strategic Partnership with Palantir Technologies
GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination
Celularity Receives Orphan Drug Designation for Natural Killer Cell Therapy CYNK-001 in the Treatment of Malignant Gliomas
Celularity Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
Celularity Announces Fast Track Designation by the FDA for our Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme
Celularity to Present at H.C. Wainwright Global Life Sciences Conference
Celularity to Present at the B. Riley Securities Virtual Oncology Investor Conference
Celularity Announces Release of 100th Cord Blood Stem Cell Unit by its Lifebank Division
Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy
Celularity Announces Positive DMC Safety Review and Continuation of its Phase I/II CYNK-001-COVID-19 (CYNKCOVID) Study
Celularity Doses First Patient in Clinical Trial Evaluating CYNK-001 in COVID-19 Patients
Celularity Announces Sales of UltraMIST® Ultrasound Healing Therapy Asset to Sanuwave Health, Inc.
Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19
Celularity Expands Strategic Collaboration with United Therapeutics Corporation to COVID-19 Infection and Acute Respiratory Distress Syndrome
Celularity Announces FDA Clearance of IND Application for CYNK-001 in Coronavirus, First in Cellular Therapy